OptimPacing trial backs left bundle branch pacing over right ventricular pacing

An international trial of 702 randomized adults found left bundle branch pacing (LBBP) lowered the hazard of death, heart failure hospitalization or pacing-induced cardiomyopathy by 59% (hazard ratio 0.41) versus right ventricular pacing (RVP); the trial was stopped early for superiority.

A flat illustration of a schematic heart showing two conduction pathways branching from a central node, one leading to a wide open chamber and the other to a narrow shadowed chamber.

CLINICAL CATALYST · CARDIAC PACING TRIAL DATA · NOVEMBER 16, 2026 · GLOBAL

Left bundle branch pacing (LBBP) cut the estimated four-year rate of death, heart failure hospitalization or pacing-induced cardiomyopathy to 8.5%, against 19.2% with standard right ventricular pacing (RVP) — a hazard ratio of 0.41 — in the OptimPacing trial of adults with atrioventricular (AV) block, a condition in which electrical signals between the heart’s upper and lower chambers are delayed or interrupted. The results were presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago on November 8, 2026, and simultaneously published in the New England Journal of Medicine.

The trial randomized 702 adults, 685 of whom were included in the analysis, with an average age of 68.4 years, across 17 centers in mainland China, Hong Kong, the United Kingdom, Poland, and the United States, running from June 2021 to January 2025, according to the AHA news release and Healio. Participants had second-degree or complete AV block, or ongoing atrial fibrillation (AF) with an average heart rate below 50 beats per minute and related symptoms. Half were randomly assigned to pacemakers using LBBP, a technique that delivers the pacing signal into part of the heart’s own electrical pathway to mimic natural activation; the other half received pacemakers using RVP, the current standard of care for heart block, which has been routinely used for decades.

59%

Left bundle branch pacing (LBBP) was associated with a 59% lower hazard (hazard ratio 0.41; 95% CI 0.23–0.75) of the composite endpoint of death, heart failure hospitalization, or pacing-induced cardiomyopathy versus right ventricular pacing, per the American Heart Association and the NEJM report summarized by Healio.

A 59% lower hazard — and no cardiomyopathy cases with LBBP

At four years, an estimated 8.5% of participants in the LBBP group had died, been hospitalized for heart failure, or developed pacing-induced cardiomyopathy (PICM) — a weakening of the heart muscle caused by the mechanical dyssynchrony of RVP — compared with 19.2% in the RVP group, per the AHA release. That corresponds to a hazard ratio of 0.41 (95% CI 0.23–0.75), which the AHA release reports as a 59% lower risk; the relative reduction implied by the four-year Kaplan-Meier rates is about 56%. The absolute difference of 10.7 percentage points at four years is the figure most directly relevant to payers and hospital systems evaluating the clinical case for procedural investment in LBBP infrastructure.

The most striking individual component is the cardiomyopathy rate. No participants in the LBBP group developed PICM, against 11.7% in the RVP group, according to the AHA release. Heart failure hospitalization occurred in 1.5% of the LBBP group versus 2.9% in the RVP group. These are components of the primary composite endpoint, not separately powered comparisons.

An independent data monitoring committee reviewed results at a planned interim analysis after a median three-year follow-up. Finding a four-year Kaplan-Meier event rate of 8.5% with LBBP versus 19.2% with RVP, the committee recommended ending the trial early because LBBP had met the study’s pre-established threshold for superiority, per the AHA release. The steering committee concurred.

The investigator’s read — and the trial’s limits

Jiangang Zou, M.D., Ph.D., a professor of cardiology at First Affiliated Hospital, Nanjing Medical University in Nanjing, China, and a study author, said that left bundle branch pacing helped the heart beat in a more natural way and was linked to fewer serious heart-related events than the standard pacing approach of right ventricular pacing, according to the AHA release. Zou added that left bundle branch pacing should be the first choice for patients with heart block who need a pacemaker — a claim that, if adopted into clinical guidelines, could carry direct procurement and training implications for hospitals and device manufacturers.

The AHA release describes the results as ‘independent, preliminary, late-breaking science’ — language the AHA applies to its late-breaking abstracts, which it notes are not peer-reviewed; the full OptimPacing manuscript, however, was published simultaneously in the peer-reviewed NEJM. Whether cardiology societies in the United States, Europe, and elsewhere move to update their AV block pacing recommendations on the basis of OptimPacing and the smaller LEAP-Block trial published in JAMA in October 2026, or require additional confirmatory evidence, will determine the pace at which LBBP adoption may translate from trial data into standard procurement and reimbursement decisions. Heart Rhythm Society President Sana Al-Khatib noted that the Prague CSP trial found generally similar results with conduction-system and right ventricular pacing, and that OptimPacing was open-label, according to TCTMD. The AHA release also notes that most participants had normal left ventricular ejection fraction (LVEF) at baseline, which may limit the generalizability of the findings to patients with pre-existing ventricular dysfunction. The release adds that early termination could overestimate the benefit of LBBP, and that all LBBP procedures used a single lead type. All-cause death did not differ significantly (7.4% vs 7.7%), according to TCTMD.

What to Watch

  1. Whether the AHA, the Heart Rhythm Society, or the European Society of Cardiology initiate guideline updates for AV block pacing in response to the OptimPacing data
  2. How device manufacturers with established RVP and LBBP portfolios may adjust capital allocation and physician training programs in response to the trial findings
  3. Payer and hospital system responses to the absolute risk difference of 10.7 percentage points in the composite endpoint, particularly regarding coverage differentiation by pacing modality
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The deeper implication of the zero PICM rate in the LBBP arm is structural: it converts a known long-term complication of the dominant pacing technique into a measurable, avoidable outcome. If that finding holds in broader populations and in guideline-updating processes, the competitive pressure could fall not on any single device maker but on the entire installed base of RVP-configured systems — and on the retraining infrastructure required to shift implanting physicians toward a technically distinct procedure.

OptimPacing Trial · Primary Composite Endpoint and Its Components

Outcome Left Bundle Branch Pacing Right Ventricular Pacing
Composite primary endpoint 8.5% 19.2%
Pacing-induced cardiomyopathy 0% 11.7%
Heart failure hospitalization 1.5% 2.9%

Source: American Heart Association news release, November 8, 2026

Why this is relevant

Patients

People with atrioventricular (AV) block assigned to left bundle branch pacing (LBBP) in the OptimPacing trial experienced a composite of death, heart failure hospitalization, or pacing-induced cardiomyopathy (PICM) in 8.5% of cases at four years, compared with 19.2% in the right ventricular pacing (RVP) group, with zero cardiomyopathy cases in the LBBP arm, according to the American Heart Association.

Industry

Device manufacturers with established right ventricular pacing portfolios may face shifting procurement demand toward LBBP-configured systems and the capital and training costs associated with a technically distinct implantation procedure, if the OptimPacing data are incorporated into clinical guidelines.

Payers

The absolute risk difference of 10.7 percentage points in the composite primary endpoint, driven largely by an 11.7% cardiomyopathy rate in the standard pacing arm versus zero in the LBBP arm, could support a clinical case for coverage differentiation by pacing modality in hospital and insurer reimbursement frameworks.

Regulators

Cardiology guideline bodies such as the American Heart Association may face pressure to evaluate whether the OptimPacing data warrant updates to AV block pacing recommendations, though the evidence comes from a trial stopped early.

Sources: American Heart Association: Novel pacemaker technique reduced cardiac events in people with a heart rhythm disorder · TCTMD: Better Outcomes With LBB vs RV Pacing for Atrioventricular Block · Healio: Left bundle branch pacing superior to right ventricular pacing for atrioventricular block · PubMed: Left Bundle-Branch Area Pacing vs Right Ventricular Pacing for Atrioventricular Block and Preserved Left Ventricular Function: The LEAP-Block Randomized Clinical Trial

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related